Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Caribou Biosciences (CRBU) EBITDA Margin (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed EBITDA Margin for 6 consecutive years, with 1250.91% as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA Margin rose 40798.0% to 1250.91% in Q3 2025 year-over-year; TTM through Dec 2025 was 1906.0%, a 41631.0% decrease, with the full-year FY2024 number at 1489.69%, down 119813.0% from a year prior.
  • EBITDA Margin was 1250.91% for Q3 2025 at Caribou Biosciences, up from 1783.95% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 41.62% in Q3 2023 to a low of 1783.95% in Q2 2025.
  • A 5-year average of 987.73% and a median of 825.1% in 2021 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: soared 81864bps in 2021, then tumbled -161728bps in 2024.
  • Caribou Biosciences' EBITDA Margin stood at 727.39% in 2021, then grew by 1bps to 717.01% in 2022, then plummeted by -31bps to 941.37% in 2023, then plummeted by -84bps to 1734.42% in 2024, then grew by 28bps to 1250.91% in 2025.
  • Per Business Quant, the three most recent readings for CRBU's EBITDA Margin are 1250.91% (Q3 2025), 1783.95% (Q2 2025), and 1734.42% (Q4 2024).